NASDAQ:ADAG

Adagene (ADAG) Stock Forecast, Price & News

$1.32

0.00 (0.00%)

(As of 03:58 PM ET)

Compare

Today's Range: $1.31
▼
$1.35
50-Day Range: $1.29
▼
$1.54
52-Week Range: $0.90
▼
$2.88

Volume: 4,205 shs
Average Volume: 18,409 shs
Market Capitalization: $57.09 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Adagene MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 273.1% Upside
$5.00 Price Target
Short Interest: Healthy
0.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.37
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.92) to ($2.05) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

618th out of 1,006 stocks

Pharmaceutical Preparations Industry

305th out of 492 stocks

3.5

Analyst's Opinion

Consensus Rating
Adagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Adagene has a forecasted upside of 273.1% from its current price of $1.34.
Amount of Analyst Coverage
Adagene has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.05% of the float of Adagene has been sold short.
Short Interest Ratio / Days to Cover
Adagene has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Adagene has recently increased by 108.51%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Adagene does not currently pay a dividend.
Dividend Growth
Adagene does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADAG.

1.9

News and Social Media Coverage

News Sentiment
Adagene has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Adagene this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adagene insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.68% of the stock of Adagene is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Adagene are expected to decrease in the coming year, from ($1.92) to ($2.05) per share.
Price to Book Value per Share Ratio
Adagene has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Adagene (NASDAQ:ADAG) Stock

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

ADAG Stock News Headlines

May 28, 2023 | americanbankingnews.com

Short Interest in Adagene Inc. (NASDAQ:ADAG) Grows By 108.5%

May 25, 2023 | finance.yahoo.com

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

May 31, 2023 | Edge On The Street (Ad)

Soaring EV Industry Keeps Investor Focus on Lithium

The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.

May 23, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Poseida Therapeutics (PSTX), Mustang Bio (MBIO)

May 16, 2023 | americanbankingnews.com

Adagene Inc. (NASDAQ:ADAG) Sees Large Decrease in Short Interest

May 4, 2023 | finance.yahoo.com

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

April 30, 2023 | americanbankingnews.com

Adagene Inc. (NASDAQ:ADAG) Short Interest Down 28.8% in April

April 28, 2023 | finance.yahoo.com

Adagene Announces Updates to its Board of Directors

May 31, 2023 | Edge On The Street (Ad)

Soaring EV Industry Keeps Investor Focus on Lithium

The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.

April 24, 2023 | americanbankingnews.com

Adagene (NASDAQ:ADAG) Given Buy Rating at HC Wainwright

April 24, 2023 | americanbankingnews.com

Adagene's (ADAG) Buy Rating Reiterated at HC Wainwright

April 22, 2023 | msn.com

HC Wainwright & Co. Reiterates Adagene Inc - ADR (ADAG) Buy Recommendation

April 21, 2023 | markets.businessinsider.com

Expert Ratings for Adagene

April 18, 2023 | finance.yahoo.com

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

April 18, 2023 | americanbankingnews.com

Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest

April 1, 2023 | americanbankingnews.com

Adagene Inc. (NASDAQ:ADAG) Sees Significant Increase in Short Interest

March 31, 2023 | msn.com

Are Medical Stocks Lagging Adagene (ADAG) This Year?

March 31, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Adagene (ADAG) This Year?

March 31, 2023 | finance.yahoo.com

Adagene Full Year 2022 Earnings: US$1.85 loss per share (vs US$1.83 loss in FY 2021)

March 31, 2023 | americanbankingnews.com

Adagene Inc. (NASDAQ:ADAG) to Post FY2023 Earnings of ($1.49) Per Share, HC Wainwright Forecasts

March 31, 2023 | americanbankingnews.com

HC Wainwright Reiterates "Buy" Rating for Adagene (NASDAQ:ADAG)

March 29, 2023 | finanznachrichten.de

Adagene Inc.: Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

March 28, 2023 | finance.yahoo.com

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

March 21, 2023 | americanbankingnews.com

Adagene (NASDAQ:ADAG) Receives Buy Rating from HC Wainwright

March 21, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Adagene (ADAG)

March 16, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Hookipa Pharma (HOOK)

March 14, 2023 | finance.yahoo.com

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

ADAG Company Calendar

Today: 5/31/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ADAG
CUSIP: N/A
CIK: 1818838
Web: www.adagene.com
Phone: 86-512-8777-3632
Fax: N/A
Employees: 198
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +274.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.17
Current Ratio: 2.71
Quick Ratio: 2.71

Sales & Book Value

Annual Sales: $9.29 million
Price / Sales: 6.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.91 per share
Price / Book: 0.70

Miscellaneous

Outstanding Shares: 43,250,000
Free Float: 34,083,000
Market Cap: $57.74 million
Optionable: Not Optionable
Beta: 0.05

Key Executives

Dr. Peter P. Luo Ph.D. (Age 56)
Co-Founder, CEO & Chairman

Mr. Man Kin Tam M.B.A. (Age 45)
CFO & Director

Dr. Fangyong Du Ph.D. (Age 52)
Chief Technology Officer

Dr. Jc Xu M.D. (Age 57)
Ph.D., Chief Scientific Officer

Ms. Ami Celeste Knoefler
VP of Investor Relations & Corp. Communications

Ms. Ling Zhou
Head of HR

Dr. Qinghai Zhao (Age 61)
Chief Manufacturing Officer

Ms. Yan Li M.B.A. (Age 47)
Sr. VP of Bioinformatics & Information Technology

Ms. Xiaohong She (Age 55)
Sr. VP & Head of Clinical Operations

Dr. Guizhong Liu Ph.D. (Age 51)
Head of Biology & Pharmacology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ADAG Stock - Frequently Asked Questions

Should I buy or sell Adagene stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ADAG shares.
View ADAG analyst ratings or view top-rated stocks.
What is Adagene's stock price forecast for 2023?: 2 analysts have issued 12-month target prices for Adagene's stock. Their ADAG share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 274.5% from the stock's current price.
View analysts price targets for ADAG or view top-rated stocks among Wall Street analysts.
How have ADAG shares performed in 2023?: Adagene's stock was trading at $1.3250 at the beginning of the year. Since then, ADAG shares have increased by 0.8% and is now trading at $1.3350.
View the best growth stocks for 2023 here.
Are investors shorting Adagene?: Adagene saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 19,600 shares, an increase of 108.5% from the April 30th total of 9,400 shares. Based on an average daily trading volume, of 10,700 shares, the short-interest ratio is currently 1.8 days. Currently, 0.1% of the shares of the company are short sold.
View Adagene's Short Interest.
When did Adagene IPO?: (ADAG) raised $133 million in an initial public offering on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies served as the underwriters for the IPO and China Renaissance was co-manager.
What is Adagene's stock symbol?: Adagene trades on the NASDAQ under the ticker symbol "ADAG."

Who are Adagene's major shareholders?: Adagene's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Strategic Vision Investment Ltd (0.81%) and Renaissance Technologies LLC (0.09%).
How do I buy shares of Adagene?: Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Adagene's stock price today?: One share of ADAG stock can currently be purchased for approximately $1.34.
How much money does Adagene make?: Adagene (NASDAQ:ADAG) has a market capitalization of $57.74 million and generates $9.29 million in revenue each year.
How many employees does Adagene have?: The company employs 198 workers across the globe.
How can I contact Adagene?: Adagene's mailing address is 4F BUILDING C14 NO. 218 XINGHU STREET SUZHOU INDUSTRIAL PARK, JIANGSU F4, 215123. The official website for the company is www.adagene.com. The company can be reached via phone at 86-512-8777-3632 or via email at ir@adagene.com.

This page (NASDAQ:ADAG) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial